

RANKINIDINE, A NEW INDOLE ALKALOID FROM
GELSEMIUM RANKINII

YEH SCHUN and GEOFFREY A. CORDELL


Program for Collaborative Research in the Pharmaceutical Sciences, College of Pharmacy,
University of Illinois at Chicago, Chicago, Illinois 60612

ABSTRACT.—A new oxindole alkaloid, rankinidine (**1**), has been isolated from the MeOH extract of the stem of *Gelsemium rankinii*. Its structure was elucidated by comparison with an analog, humanenirine (**3**), which also occurred in this plant.

Gelsemium rankinii Small (Loganiaceae) is a rare species native to the southeastern United States (1), which, until we recently reported (2) the isolation of a new oxindole alkaloid, 21-oxogelsevirine, was previously uninvestigated. Continued fractionation has led to the isolation and structure elucidation of another new oxindole alkaloid, rankinidine (**1**).

Rankinidine (**1**) was obtained as white needle crystals, $[\alpha]^{20}_D -126$ (c 0.07, MeOH), decomposing quite rapidly to an orange brown amorphous gum, even at 5°. Its ir spectrum showed absorptions at 3300, 1722, 1716, 1698, 1466, and 753 cm^{-1} , and uv absorptions were noted at 217 and 256 nm revealing the characteristic oxindole alkaloid nucleus (3,4). The mass spectrum of compound **1** exhibited a molecular ion peak at 340, the facile loss of a methoxy group from the molecular ion, and an ion at m/z 164 ($M^+ - 176$), due to the loss of the aromatic portion. Such a fragmentation pattern was in agreement with that of humanenine (**2**), which exhibited an additional ion involving the loss of an *N*-methyl group.

Humanenirine (**3**) and humanenine (**2**) were both recently isolated from a Chinese *Gelsemium* species (*G. elegans*). They possess a different carbon framework than either gelsemine or gelsedine, and this was established for **2** through X-ray analysis (5,6).



	R ₁	R ₂
1	H	H
2	CH ₃	H
3	H	OCH ₃

Comparison of the ¹H-nmr spectrum of **1** with that reported for **2** indicated a close agreement but that **1** lacked an N-CH₃ group at 2.34 ppm. High resolution nmr (360 MHz), however, did provide an unambiguous assignment for H-21, H-6, H-14, and H-16 which were not identified in the original reports.

The high-field ¹H nmr of **3**, which is also present in *G. rankinii*, showed three aromatic protons at 7.30, 6.62, and 6.56 ppm for H-9, H-10, and H-12, respectively. A methoxy group at 3.83 ppm displayed the nOe with H-10 and H-12, establishing substitution at C-11 of the aromatic nucleus. From the homonuclear COSY spectrum, two H-21 protons at 3.87 and 3.32 ppm were correlated to H-19 and 5.23 ppm and H-18 at 1.59 ppm, respectively, and the signal at 3.32 ppm displayed a small coupling ($J = 1.1$ Hz) in addition to geminal coupling ($J = 16.8$ Hz). This proton was assigned to H-21 α due to the long range coupling with the olefinic H-19 and a small W coupling

with H-15, as shown in the COSY spectrum. The assignments of H-17 α at 4.29 ppm and H-17 β at 4.02 ppm were in accordance with the observation that only H-17 β was coupled with H-16 at 2.20 ppm. On the other hand, H-17 α was the only proton exhibiting a nOe effect with H-6 β at 2.30 ppm; consequently, the signal at 2.18 ppm was assigned to H-6 α .

The limited sample of rankinidine available prevented an examination of its COSY spectrum. However, unambiguous assignment proton assignments could be made through a comparison with the assigned spectrum of humantenirine as shown in Table 1.

TABLE 1. ^1H -nmr Spectral Data of Rankinidine (1) and Humantenirine (3)^a

Proton	Compounds	
	1 ^b	3
3	3.56, d, 7.7	3.52, d, 8.4
5	3.84, m	3.68, m
6 α	2.19, dd, 3.3, 15.3	* 2.18, dd, 3.3, 15.3
6 β	2.30, dd, 3.3, 15.3	2.30, dd, 3.2, 15.6
9	7.42, d, 7.4	7.30, dd, 0.8, 8.4
10	7.14, t, 7.4	6.62, dd, 1.6, 8.4
11	7.41, t, 7.4	—
12	6.98, d, 7.4	6.56, d, 1.6
14 α	2.38, dd, 7.0, 13.7	2.42, dd, 7.3, 15.6
14 β	2.30, dd, 7.7, 13.7	2.30, dd, 8.4, 15.6
15	2.64, m	2.60, m
16	2.20, m	2.20, m
17 α	4.33, d, 10.6	4.29, d, 10.5
17 β	4.05, dd, 4.3, 10.6	4.03, dd, 4.2, 10.5
18	1.61, d, 6.8	1.59, d, 6.8
19	5.28, q, 6.8	5.23, q, 7.0
21 α	3.37, dd, 2.7, 16.2	3.32, dd, 1.1, 16.8
21 β	3.93, d, 16.2	3.87, d, 16.8
Ar-OCH ₃ . . .	—	3.83, s
N-OCH ₃ . . .	4.00, s	3.98, s

^aRecorded at 360 MHz in CDCl₃.

^bChemical shift in ppm; multiplicity; J in Hz.

Humantenirine and humantenine were isolated from both American *Gelsemium* species, i.e., *G. sempervirens* and *G. rankinii*. Rankinidine was obtained from *G. rankinii*, but not from *G. sempervirens*. Because of the instability of both rankinidine and humantenirine, their ^{13}C -nmr spectra were not available for examination.

EXPERIMENTAL

GENERAL EXPERIMENTAL PROCEDURES.—The melting point was determined by means of a Kofler hotplate and is uncorrected. Uv spectra were obtained with a Beckman model DU-7 spectrophotometer. The ir spectrum was determined on a Nicolet MX-1 interferometer. ^1H -nmr spectra were recorded on a Nicolet NMC 360 (360 MHz) using CDCl₃ as a solvent and TMS as an internal standard. The mass spectra were obtained with a Finnigan/MAT 112S double focussing mass spectrometer operating at 70 eV. The optical rotation was measured with a Perkin-Elmer, Model 241 polarimeter. Silica gel for chromatography was purchased from E. Merck, Darmstadt, W. Germany, and preparative tlc plates were from Analtech, Newark, Delaware.

PLANT MATERIAL.—Dried stem material of *G. rankinii* was collected in the spring of 1984 and identified by Dr. M. Garland. Voucher specimens were deposited in the Field Museum of Natural History, Chicago, Illinois.

EXTRACTION AND PURIFICATION.—Chopped stems of *G. rankinii* (300 g) were percolated with MeOH at room temperature for 2 days, five times. The combined MeOH extracts were concentrated in vacuo at 30° to afford a thick dark syrup (ca. 35 g), which was dissolved in 2% citric acid and partitioned against Et₂O. After removal of the Et₂O extract, the acidic layer was basified with aqueous NH₃ to pH 8.0 and extracted extensively with EtOAc until a Dragendorff test was negative. The process was completed within the same day to avoid decomposition. The total alkaloid extract (2.5 g) was subjected to silica gel column chromatography eluting with mixtures of petroleum ether, EtOAc, and MeOH of increasing polarity.

ISOLATION OF RANKINIDINE (1).—The petroleum ether-EtOAc-MeOH (60:40:3) eluent (0.12 g) from the column chromatography was subjected to repeated preparative tlc using petroleum ether-C₆H₆-EtOAc-diethyl amine (25:10:10:4) as a solvent system, and a purple band under uv light at Rf 0.25 was eluted with Me₂CO to afford white needles of **1** (6 mg, became less than 2 mg after 2 weeks in cold room), mp 175-178° (Me₂CO); $[\alpha]^{20}_D -126$ (c 0.07, MeOH); uv λ max (MeOH) 217 (log ϵ 4.02) and 256 (3.75); ir ν max (AgCl) 3300, 1722, 1716, 1698, 1466, 753 cm⁻¹; ¹H nmr, see table 1; ms *m/z* (rel. int.) 340 (M⁺, 26), 325 (5), 309 (20), 164 (29), 149 (21), 108 (100).

ISOLATION OF HUMANTENIRINE (3).—From the same eluent as compound **1** and the same preparative tlc process, compound **3** was isolated at Rf 0.20 as white needles (1 mg), mp 167-170° (Me₂CO); $[\alpha]^{20}_D -135$ (c 0.56, MeOH); uv λ max (MeOH) 226 (log ϵ 4.24, 261 (3.59)); ir ν max (AgCl) 1722, 1717, 1632, 1622, 1467, 1462, 1221, 1215, 758 cm⁻¹; ¹H nmr, see table 1; ms *m/z* (rel. int.) 370 (M⁺, 33), 355 (1), 339 (20), 164 (100), 108 (90). The ¹H nmr study was made possible through the availability of **3** from *G. sempervirens*.

ACKNOWLEDGMENTS

This work was supported, in part, by the Division of Cancer Treatment, National Cancer Institute through grant CA-20164. We gratefully acknowledge the Nuclear Magnetic Resonance and Mass Spectrometric Laboratories of the Research Resources Center, University of Illinois at Chicago, for providing the equipment necessary to conduct this study.

LITERATURE CITED

1. R. Ornduff, *J. Arn. Arbor.*, **51**, 1 (1970).
2. S. Yeh and G.A. Cordell, *J. Nat. Prod.*, **49**, 483 (1986).
3. S. Yeh and G.A. Cordell, *J. Nat. Prod.*, **48**, 788 (1985).
4. S. Yeh and G.A. Cordell, *J. Nat. Prod.*, **48**, 969 (1985).
5. J.S. Yang and Y.W. Chen, *Acta Pharm. Sinica*, **19**, 399 (1984).
6. J.S. Yang and Y.W. Chen, *Acta Pharm. Sinica*, **19**, 686 (1984).

Received 20 January 1986